arrow
M

Michael W. Bishop

University of Tennessee Health Science Center
H指数:25
被引数:2,995

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma

ESFT13:一项评估在标准化疗基础上增加窗口期治疗和维持治疗以治疗高危尤因肉瘤的II期研究

2025-09-040
OAAI
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2022-09-0112
OA
Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences

儿童癌症幸存者的原发性甲状腺功能减退症: 患病率,危险因素和长期后果

CANCER
IF5.1
2021-10-137
OAAI
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

talazoparib和伊立替康联合或不联合替莫唑胺在患有复发性或难治性实体恶性肿瘤的儿童和年轻人中的I期试验

2020-09-0144
PREAI
Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study
2019-11-1038
OAAI
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
CANCER
IF5.1
2019-07-2987
OAAI
The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)

幸存的儿童癌症的累积负担: 来自圣犹达终身队列研究 (SJLIFE) 的初步报告

LANCET
IF88.5
2017-12-01584
OAAI